
## Timothy E Van Meter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11927870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence and Correlates of Depressive Symptoms Within 6 Months After First-Time Mild Traumatic Brain Injury. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 367-377.	1.8	2
2	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
3	A Prognostic Model for Predicting One-Month Outcomes among Emergency Department Patients with Mild Traumatic Brain Injury and a Presenting Glasgow Coma Scale of Fifteen. Journal of Neurotrauma, 2021, 38, 2714-2722.	3.4	13
4	Age differences in outcome after mild traumatic brain injury: results from the HeadSMART study. International Review of Psychiatry, 2020, 32, 22-30.	2.8	12
5	Clinical Gestalt for Early Prediction of Delayed Functional and Symptomatic Recovery From Mild Traumatic Brain Injury Is Inadequate. Academic Emergency Medicine, 2019, 26, 1384-1387.	1.8	10
6	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
7	Loss of consciousness and altered mental state predicting depressive and post-concussive symptoms after mild traumatic brain injury. Brain Injury, 2019, 33, 1064-1069.	1.2	12
8	Influence of study population definition on the effect of age on outcomes after blunt head trauma. Brain Injury, 2018, 32, 1725-1730.	1.2	4
9	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
10	Prevalence of Incomplete Functional and Symptomatic Recovery among Patients with Head Injury but Brain Injury Debatable. Journal of Neurotrauma, 2017, 34, 1531-1538.	3.4	15
11	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
12	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
13	EG-17 * SUV420-MEDIATED HETEROCHROMATIN CHANGES IN PEDIATRIC BRAIN CANCERS. Neuro-Oncology, 2014, 16, v78-v78.	1.2	0
14	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
15	Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. Journal of Neurosurgery, 2012, 116, 843-853.	1.6	37
16	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
17	Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. Journal of Neurosurgery, 2010, 112, 18-25.	1.6	23
18	Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways. Molecular Cancer Research, 2010, 8, 35-45.	3.4	95

#	Article	IF	CITATIONS
19	Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Molecular Cancer Therapeutics, 2008, 7, 3519-3526.	4.1	87
20	Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. Journal of Neurosurgery, 2007, 107, 586-592.	1.6	23
21	Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. Journal of Neuro-Oncology, 2007, 83, 163-172.	2.9	11
22	Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer, 2006, 107, 2446-2454.	4.1	17
23	Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro-Oncology, 2004, 6, 188-199.	1.2	39